Table 3 Comparisons between patients with CD diagnosed in the prebiologic and biologic era.
Prebiologic era | Biologic era | P value | |
|---|---|---|---|
Number of patients | 245 (45.2%) | 280 (51.7%) | |
Gender, male (n [%]) | 133 (54.3%) | 158 (56.4%) | 0.622 |
Age at the time of diagnosis, years, Mean (SD) | 33.9 (13.6) | 38.8 (16.1) | < 0.001 |
Disease duration, years, Mean (SD) | 18.4 (7.96) | 4.1 (2.68) | < 0.001 |
Lichtiger index at diagnosis, Mean (SD) | 3.05 (2.4) | 3.25 (2.8) | 0.393 |
Treatment | |||
Biologics and small molecule agents | 53 (21.6%) | 90 (32.1%) | 0.007 |
IFX (n [%]) | 28 (11.4%) | 37 (13.2%) | 0.535 |
IFX-BS (n [%]) | 15 (6.1%) | 23 (8.2%) | 0.356 |
ADA (n [%]) | 18 (7.3%) | 28 (10.0%) | 0.283 |
GLM (n [%]) | 5 (2.0%) | 20 (7.1%) | 0.006 |
VED (n [%]) | 1 (0.4%) | 5 (1.8%) | 0.138 |
Tofacitinib (n [%]) | 5 (2.0%) | 14 (5.0%) | 0.069 |
Other treatment | |||
5-ASA (n [%]) | 226 (92.2%) | 246 (87.9%) | 0.096 |
Corticosteroids | 165 (67.3%) | 179 (63.9%) | 0.411 |
Immunomodulator (n [%]) | 104 (42.4%) | 96 (34.3%) | 0.055 |
Calcineurin inhibitor (n [%]) | 44 (18.0%) | 37 (13.2%) | 0.141 |
Apheresis (n [%]) | 80 (32.7%) | 65 (23.2%) | 0.014 |
Probiotics (n [%]) | 191 (78.0%) | 209 (74.6%) | 0.519 |
Herbal drug (n [%]) | 30 (12.2%) | 27 (9.6%) | 0.342 |
